Market Trends, Business Strategies, Competitive Intelligence, Clinical Trials, and Patent Trends Driving Growth from 2024 to 2029"Boston, July 10, 2025 (GLOBE NEWSWIRE) -- According to the latest ...

T-bet is a transcription factor, one of the control proteins in the cell nucleus that can turn specific groups of genes on ...

Cartesian's mRNA-based cell therapy offers a novel, outpatient approach for autoimmune diseases. Promising results, but Phase ...

Researchers found that psilocybin, from psychedelic mushrooms, extended cell lifespan and helped aging mice live longer and ...

There are few scientific methods more elegantly simple than "just sprinkle it on top." Researchers at Tohoku University and ...

New report adds to growing evidence of iNKT cell therapy’s potential in solid tumors. NEW YORK, July 11, 2025 (GLOBE NEWSWIRE ...

Antibody–siRNA conjugates (ARCs) are a type of promising drug modalities for cancer therapy. However, initial reports of ARCs present the gene knockdown effect only in limited tissues (e.g., muscles) ...

Immix Biopharma, Inc. (“ImmixBio”, “Company”, “We” or “Us” or ”IMMX”), a clinical-stage biopharmaceutical company developing cell therapies for AL Amyloidosis and other serious diseases, today ...

Results of a phase 1 clinical trial for patients with melanoma show that an updated formula and delivery of the NeoVax ...

IGI Therapeutics has signed an exclusive licensing agreement with AbbVie, for ISB 2001 to treat cancer and autoimmune diseases.

Researchers are making ever more sophisticated mini organs in the lab — and now they can grow their own blood vessels. The ...

A team at the Peter Mac is planning for first-in-human trials in five years, hoping this new therapy will eschew the ...